Research Grade Sotrovimab (DVV00307)

Catalog No.

DVV00307

Expression system

Mammalian Cells

Species reactivity

SARS-CoV-2 (2019-nCoV)

Host species

Human

Isotype

IgG1, kappa

Clonality

Monoclonal

Target

Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2, Spike protein S2', S, 2

Concentration

3.03 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P0DTC2

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

VIR-7831, GSK4182136, S309, CAS: 2423014-07-5

Clone ID

Sotrovimab

Sotrovimab, PMID: 34165945

An EUA for sotrovimab for treatment of COVID-19, PMID: 34181630

COVID antibody treatments show promise for preventing severe disease, PMID: 33712752

Effects of the glycosylation of the receptor binding domain (RBD dimer)-based Covid-19 vaccine (ZF2001) on its humoral immunogenicity and immunoreactivity. [DVV00307]

Document Download

Research Grade Sotrovimab.pdf